DOCSLIB.ORG

Overexpression of the CD155 Gene in Human Colorectal Carcinoma Gut: First Published As 10.1136/Gut.49.2.236 on 1 August 2001

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Overexpression of the CD155 Gene in Human Colorectal Carcinoma Gut: First Published As 10.1136/Gut.49.2.236 on 1 August 2001 236 Gut 2001;49:236–240 Overexpression of the CD155 gene in human colorectal carcinoma Gut: first published as 10.1136/gut.49.2.236 on 1 August 2001. Downloaded from D Masson, A Jarry, B Baury, P Blanchardie, C Laboisse, P Lustenberger, M G Denis Abstract monoclonal antibodies (E4) reacts strongly Background and aims—The Ta ge 4 gene with the primary tumours and lung metastases, (tumour associated glycoprotein E4) is as determined by immunohistochemistry. The overexpressed in rat colon tumours and epithelia of the gastrointestinal tract and of the Min mouse intestinal adenomas. The rat bronchi are only slightly stained and no Tage4 protein has approximately 40% staining of other normal rat tissues is observed. identity with human CD155, a member of Initial experiments have indicated that the the immunoglobulin superfamily coding antigen recognised by E4 is a transmembrane for a transmembrane protein capable of glycoprotein.23The corresponding Ta g e 4 gene serving as an entry receptor for polio- (tumour associated glycoprotein E4) has since virus, porcine pseudorabies virus, and been found to be overexpressed in chemically bovine herpesvirus 1. Analysis of the rat induced rat colon tumours4 and in Min mouse Ta ge 4 gene has revealed structural and intestinal adenomas.5 In contrast, a barely functional similarities with the human detectable level was found in the normal adult CD155 gene. We therefore investigated rat and mouse tissues tested. The Ta g e 4 cDNA expression of the CD155 gene in human has been isolated.6 Sequence analysis using colorectal carcinomas. ALIGNp software revealed 40.9% identity Methods—Overall CD155 expression was between the Tage4 protein and the human 7 assessed by semiquantitative reverse CD155 a member of the immunoglobulin (Ig) transcription-polymerase chain reaction superfamily coding for a transmembrane pro- (RT-PCR) and immunohistochemical tein capable of serving as an entry receptor for analysis using tissue specimens from poliovirus, porcine pseudorabies virus, and patients with colorectal adenomas and bovine herpesvirus 1. The Ta g e 4 gene has been 8 adenocarcinomas. We also used a qualita- mapped to rat chromosome 1q22 and mouse 9 tive RT-PCR assay to determine relative 7A2-B1, regions that are homologous to the expression of diVerent splicing variants in long arm of human chromosome 19 where the 10 each sample. CD155 gene is located. To gain insight into Results—mRNA levels of CD155 were the molecular mechanisms involved in its over- http://gut.bmj.com/ expression in cancer cells, we isolated and increased in six of six colorectal cancer 11 tissues compared with the tumour free characterised the rat Ta g e 4 gene. This gene ∼ colon mucosa. Immunohistochemical covers 15 kb and is composed of eight exons analysis revealed an increased level of and seven introns. The human CD155 gene CD155 protein in 12 of 12 samples. The also contains seven introns in identical posi- qualitative RT-PCR assay revealed that tions and phases. In addition, the protein relative expression of the diVerent CD155 encoded by the Ta g e 4 gene was tested for abil- on October 2, 2021 by guest. Protected copyright. variant transcripts was similar in the ity to mediate entry of several viruses. The diVerent normal and cancer samples results indicated that the Ta g e 4 gene is tested, indicating that this overexpression probably orthologous to the gene for CD155. is not associated with a particular mRNA We therefore decided to analyse expression of Laboratoire de variant generated by alternative splicing the CD155 gene in human colorectal carci- Biochimie Médicale, of the CD155 gene. noma (CRC). This was performed by reverse Faculté de Médecine, transcription-polymerase chain reaction (RT- 44035 Nantes, France Conclusion—We have shown for the first time that the CD155 gene is overexpressed PCR) analysis and by immunohistochemistry. D Masson We also analysed relative expression of the dif- B Baury in colorectal carcinoma and that this P Blanchardie overexpression begins at an early stage in ferent variants of the CD155 gene by a qualita- P Lustenberger tumorigenesis and continues to late tive RT-PCR assay. M G Denis stages. (Gut 2001;49:236–240) Materials and methods INSERM U539, Faculté TISSUE SAMPLES de Médecine, 44035 Keywords: CD155; colorectal cancer; immunoglobulin Tissue samples were obtained from 18 patients Nantes, France superfamily; poliovirus receptor AJarry (10 men and eight women; mean age 66 years, C Laboisse range 45–90) undergoing surgical resections for primary CRC diagnosed at the Department Correspondence to: As our understanding of the biology of of Surgery, Nantes University Hospital, Dr MG Denis, Laboratoire colorectal cancer progresses, new knowledge de Biochimie Spécialisée, France. Adenomas were collected from four Institut de Biologie, 9 quai about tumorigenesis and tumour biology can patients: two villous adenoma (both high grade Moncousu, F-44035 Nantes be used to diagnose, treat, and prevent this type Cedex, France. of cancer. In an initial study of an animal model [email protected] Abbreviations used in this paper: CRC, colorectal for immunotherapy of colon tumours, mono- carcinoma; RT-PCR,reverse transcription-polymerase Accepted for publication clonal antibodies directed against rat colon chain reaction; CAM, cellular adhesion molecule; 29 January 2001 carcinoma cells were raised.1 One of these CEA, carcinoembryonic antigen; Ig, immunoglobulin. www.gutjnl.com CD155 and colorectal cancer 237 dysplasia) and two tubular adenomas (one low heated at 72°C for three minutes and then grade and one high grade dysplasia). Sporadic cooled on ice. It was combined with 0.5 µg of tumours were collected from 14 patients and random hexamers (Promega, Lyon, France), classified according to Astler and Coller: stage transcription buVer (50 mM Tris HCl, pH 8.3, Gut: first published as 10.1136/gut.49.2.236 on 1 August 2001. Downloaded from B (n=4), stage C (n=7), and stage D (n=3). 75 mM KCl, 3 mM MgCl2, 10 mM DTT), The tumours were localised in the right colon dNTPs (1 mM each), RNasin (50 units; (n=5), transverse colon (n=2), left colon Promega), and RNaseH− M-MLV reverse (n=3), sigmoid (n=2), and rectum (n=2). transcriptase (200 units; Promega) in a final Thirteen tumours presented a moderate diVer- volume of 20 µl. Incubation was performed at entiation, and one was highly diVerentiated. 42°C for 60 minutes. From each patient tumour tissue and adjacent normal mucosa (about 10 cm from the SEMIQUANTITATIVE EXPRESSION OF THE CD155 tumour) were excised and collected. Samples GENE were immediately processed for isolation of Amplifications were performed with 3 µl of epithelial cells and fragments were frozen for cDNA in a total volume of 50 µl containing 10 immunohistochemistry and kept at −70°C mM Tris HCl, pH 9.0, 50 mM KCl, 1.5 mM until analysis. MgCl2, 0.1% Triton X-100, 0.2 mg/ml gelatin, 200 µM of each dNTP, 100 pmol of specific NORMAL COLONIC EPITHELIAL CELLS AND primers, and 2.5 units of Taq DNA polymerase CANCER CELL LINES (Promega). Normal epithelial cells were isolated from sur- Primers were designed from the published gical specimens using a non-enzymatic disso- sequence of the human CD155 gene.10 They ciation technique based on the use of the were designed to amplify cDNA but not calcium chelating agent EDTA, as previously contaminating genomic DNA. The primers described.12 used to quantify expression of the CD155 gene HCT8R, SW620, and SW1116 colon carci- were located in a region corresponding to the noma cell lines were grown in RPMI-1640 extracellular domain of the protein, which is containing L-glutamine and sodium bicarbo- conserved in all splice variants (fig 1). The nate (Sigma, Saint Quentin Fallavier, France) sequences of these primers were: CD1–5' supplemented with 10% fetal calf serum, peni- primer: 5'-TATCTGGCTCCGAGTGCTT cillin (100 units/ml), and streptomycin (0.1 GCC-3'; CD2–3' primer: 5'-ATCATAGCCA mg/ml). Cells were maintained at 37°Cin5% GAGATGGATACC-3'. carbon dioxide and passaged twice a week. For semiquantitative amplification, each cycle was carried out at 92°C for 30 seconds, IMMUNOHISTOCHEMISTRY 62°C for 30 seconds, and 72°C for 60 seconds. Cryostat sections (5 µm) were fixed in acetone The reaction was stopped after 18 cycles, in the and stored at −20°C. Before use, slides were linear range of the amplification (not shown). http://gut.bmj.com/ rehydrated with phosphate buVered saline (150 Following electrophoresis, amplified DNA was mM NaCl, 10 mM phosphate buVer, pH 7.4). transferred to Hybond N+ membranes (Amer- The slides were then incubated with normal sham Pharmacia Biotech, Orsay, France). The goat serum for 10 minutes. Mouse monoclonal nylon filter was hybridised using alkaline phos- antibody D171 (Neomarkers, Union City, phatase labelled probes using the AlkPhos sys- California, USA) directed against human tem (Amersham Pharmacia Biotech). For CD15513 was used as a primary antibody at a CD155, a 362 bp insert amplified by PCR concentration of 2.5 µg/ml in antibody diluent from HCT8R cell cDNA with oligonucleotides on October 2, 2021 by guest. Protected copyright. containing background reducing components CD1 and CD2 was used as a probe. (Dako, Trappes, France). Alkaline phosphatase Normalisation was performed by RT-PCR goat antimouse Ig (Sigma) was used as a amplification and hybridisation of â-actin secondary antibody (dilution 1:50). Following cDNA. Fourteen cycles (92°C for 30 seconds, two washes with phosphate buVered saline and 58°C for 30 seconds, 72°C for 30 seconds) one with Tris buVered saline (150 mM NaCl, were performed with oligonucleotides B1 10 mM Tris Cl, pH 7.5), staining was (5'-CCTTCCTGGGCATGGAGTCCT-3') developed using the Vector Red alkaline phos- and B2 (5'-GGAGCAATGAT-CTTGATCT phatase substrate (Vector, Burlingame, Califor- TC-3').
Load more

Recommended publications
  • Prediction of Distant Metastasis by Using Reverse Transcriptase Polymerase Chain Reaction for Epithelial and Variant CD44 Mrna I
    ORIGINAL ARTICLE Prediction of Distant Metastasis by Using Reverse Transcriptase–Polymerase Chain Reaction for Epithelial and Variant CD44 mRNA in the Peripheral Blood of Patients With Colorectal Cancer Shozo Yokoyama, MD; Hiroki Yamaue, MD Background: Reverse transcriptase–polymerase chain Main Outcome Measure: The clinical significance of reaction (RT-PCR) has been used to identify small num- RT-PCR for epithelial and variant CD44 mRNA in pe- bers of tumor cells. Molecular detection is thought to pro- ripheral blood. vide useful information for the clinical management of postoperative adjuvant therapy regimens. Results: During 3 years of follow-up, 2 patients whose peripheral blood had carcinoembryonic antigen and Objective: To use RT-PCR to identify messenger RNA CD44 variant mRNA also had distant metastases (lung (mRNA) coding for carcinoembryonic antigen, epithelial or spleen). Expression of epithelial and variant CD44 and variant CD44, and matrix metalloproteinase 7 in the mRNA in peripheral blood was more highly correlated portal venous and peripheral blood of patients with colo- with the clinical cancer stage than with expression rectal carcinoma to predict live or distant metastasis. of carcinoembryonic antigen and matrix metallopro- teinase 7. Design: Prospective consecutive series. Conclusions: Molecular detection of epithelial and Setting: University hospital. variant CD44 mRNA in the peripheral blood may help determine distant metastases in patients with colorectal Patients and Methods: Portal venous and peripheral carcinoma. Molecular detection in the peripheral blood blood samples were obtained from 22 patients with colo- at surgical treatment suggests that systemic hemato- rectal cancer during surgical manipulation. Using comple- genic tumor cell dissemination is an early event of dis- mentary DNA primers specific for carcinoembryonic tant metastasis.
    [Show full text]
  • CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery
    in vivo 32 : 1533-1540 (2018) doi:10.21873/invivo.11411 CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery CHIH-PO HSU 1* , LI-YU LEE 2* , JUN-TE HSU 1, YU-PAO HSU 1, YU-TUNG WU 1, SHANG-YU WANG 1, CHUN-NAN YEH 1, TSE-CHING CHEN 2 and TSANN-LONG HWANG 1 1Department of General Surgery, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan, R.O.C.; 2Department of Pathology, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan, R.O.C. Abstract. Background/Aim: Pancreatic ductal adeno- predicted ER. Conclusion: High CA19-9 levels, CD44 H- carcinoma (PDAC) is one of the most aggressive types of scores and poor differentiation are independent predictors digestive cancer. Recurrence within one year after surgery is for ER in PDAC patients undergoing radical resection. inevitable in most PDAC patients. Recently, cluster of Therefore, the determination of CD44 expression might help differentiation 44 (CD44) has been shown to be associated in identifying patients at a high risk of ER for more with tumor initiation, metastasis and prognosis. This study aggressive treatment after radical surgery. aimed to explore the correlation of CD44 expression with clinicopathological factors and the role of CD44 in Pancreatic ductal adenocarcinoma (PDAC) is the fourth most predicting early recurrence (ER) in PDAC patients after common cause of cancer-related death worldwide, with an radical surgery. Materials and Methods: PDAC patients who 8% 5-year survival rate for all stages of disease (1). underwent radical resection between January 1999 and Although various treatment modalities are available, only March 2015 were enrolled in this study.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • The Role of the Carcinoembryonic Antigen Receptor in Colorectal Cancer Progression
    gra nte tive f I O o l n a c o n r l o u g o y J Bajenova et al., J Integr Oncol 2017, 6:2 Journal of Integrative Oncology DOI: 10.4172/2329-6771.1000192 ISSN: 2329-6771 Research Article Open Access The Role of the Carcinoembryonic Antigen Receptor in Colorectal Cancer Progression Olga Bajenova1,2, Elena Tolkunova3, Sergey Koshkin3, Sergey Malov1, Peter Thomas4, Alexey Tomilin3 and Stephen O’Brien1 1Theodosius Dobzhansky Center for Genome Bioinformatics at St. Petersburg State University, St. Petersburg, Russia 2Department of Genetics and Biotechnology, St. Petersburg State University, St. Petersburg, Russia 3Institute of Cytology, Russian Academy of Sciences, St. Petersburg, Russia 4Department of Surgery, Creighton University, Omaha, USA *Corresponding author: Olga Bajenova, Theodosius Dobzhansky Center for Genome Bioinformatics at St. Petersburg State University, 41-43 Sredniy Prospekt, St Petersburg, Russia, Tel: +7-812-363-6103; E-mail: [email protected] Received Date: March 25, 2017; Accepted Date: April 18, 2017; Published Date: April 28, 2017 Copyright: © 2017 Bajenova O, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Clinical and experimental data suggest that carcinoembryonic antigen (CEA, CD66e, CEACAM-5) plays a key role in the formation of hepatic metastasis from colorectal and other types of epithelial cancers. The molecular events involved in CEA-induced metastasis have yet to be defined. Our group first cloned the gene (CEAR) for CEA- binding protein from the surface of fixed liver macrophages, (Kupffer cells).
    [Show full text]
  • Soluble Carcinoembryonic Antigen Activates Endothelial Cells and Tumor Angiogenesis
    Published OnlineFirst October 11, 2013; DOI: 10.1158/0008-5472.CAN-13-0123 Cancer Microenvironment and Immunology Research Soluble Carcinoembryonic Antigen Activates Endothelial Cells and Tumor Angiogenesis Kira H. Bramswig1, Marina Poettler1, Matthias Unseld1, Friedrich Wrba2, Pavel Uhrin3, Wolfgang Zimmermann4, Christoph C. Zielinski1, and Gerald W. Prager1 Abstract Carcinoembryonic antigen (CEA, CD66e, CEACAM-5) is a cell-surface–bound glycoprotein overexpressed and released by many solid tumors that has an autocrine function in cancer cell survival and differentiation. Soluble CEA released by tumors is present in the circulation of patients with cancer, where it is used as a marker for cancer progression, but whether this form of CEA exerts any effects in the tumor microenvironment is unknown. Here, we present evidence that soluble CEA is sufficient to induce proangiogenic endothelial cell behaviors, including adhesion, spreading, proliferation, and migration in vitro and tumor microvascularization in vivo. CEA-induced activation of endothelial cells was dependent on integrin b-3 signals that activate the focal- adhesion kinase and c-Src kinase and their downstream MAP–ERK kinase/extracellular signal regulated kinase and phosphoinositide 3-kinase/Akt effector pathways. Notably, while interference with VEGF signaling had no effect on CEA-induced endothelial cell activation, downregulation with the CEA receptor in endothelial cells attenuated CEA-induced signaling and tumor angiogenesis. Corroborating these results clinically, we found
    [Show full text]
  • Role of Liver ICAM‑1 in Metastasis (Review)
    ONCOLOGY LETTERS 14: 3883-3892, 2017 Role of liver ICAM‑1 in metastasis (Review) AITOR BENEDICTO, IRENE ROMAYOR and BEATRIZ ARTETA Department of Cell Biology and Histology, School of Medicine and Nursing, University of The Basque Country, UPV/EHU, Leioa, E-48940 Vizcaya, Spain Received January 17, 2017; Accepted July 7, 2017 DOI: 10.3892/ol.2017.6700 Abstract. Intercellular adhesion molecule (ICAM)-1, is a frequently diagnosed cancer types and is the fourth leading transmembrane glycoprotein of the immunoglobulin (Ig)-like cause of cancer-related death (1). The spreading of cells from superfamily, consisting of five extracellular Ig‑like domains, a the primary lesion to a secondary organ and the subsequent transmembrane domain and a short cytoplasmic tail. ICAM-1 is development of distant metastases is a key factor that limits expressed in various cell types, including endothelial cells and patient survival rate. This remains one of the most complex leukocytes, and is involved in several physiological processes. issues faced in medicine (2). Furthermore, it has additionally been reported to be expressed The liver is the main target organ for metastatic CRC in various cancer cells, including melanoma, colorectal cancer cells and the second most commonly invaded organ, after and lymphoma. The majority of studies to date have focused the lymph nodes (3). In fact, 15-25% of CRC patients present on the expression of the ICAM‑1 on the surface of tumor cells, with synchronous hepatic metastases at the time of diagnosis, without research into ICAM‑1 expression at sites of metastasis. and a further 30% will later develop liver metastasis (4,5).
    [Show full text]
  • The Immunomodulatory CEA Cell Adhesion Molecule 6 (CEACAM6/Cd66c) Is a Candidate Receptor for the Influenza a Virus
    bioRxiv preprint doi: https://doi.org/10.1101/104026; this version posted January 30, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 The immunomodulatory CEA cell adhesion molecule 6 (CEACAM6/CD66c) is a 2 candidate receptor for the influenza A virus 3 Shah Kamranur Rahmana *, Mairaj Ahmed Ansarib, Pratibha Gaurc, Imtiyaz Ahmada, 4 Chandrani Chakravartya,d, Dileep Kumar Vermaa, Sanjay Chhibbere, Naila Nehalf, 5 Shanmugaapriya Sellathanbyd, Dagmar Wirthc, Gulam Warisb and Sunil K. Lala,g # 6 7 Virology Group, International Centre for Genetic Engineering & Biotechnology, New Delhi, 8 Indiaa. 9 Department of Microbiology and Immunology, H. M. Bligh Cancer Research Laboratories, 10 Rosalind Franklin University of Medicine and Science, Chicago Medical School, North 11 Chicago, Illinois, USAb. 12 Helmholtz Centre for Infection Research, Braunschweig, Germanyc. 13 Department of Biomedical Science, Bharathidasan University, Trichy, Indiad. 14 Microbiology Department, Panjab University, Chandigarh, Indiae. 15 Career Institute of Medical & Dental Sciences and Hospital, Lucknow, Indiaf. 16 School of Science, Monash University, Selangor DE, Malaysiag. 17 18 Running Head: Protein receptor for Influenza A Virus 19 20 # Corresponding author: Professor of Microbiology, School of Science, Monash University, 21 47500 Bandar Sunway, Selangor DE, Malaysia. 22 Email: [email protected]; Telephone: (+603) 551 59606 23 24 * Current address: Department of Pathogen Molecular Biology, London School of Hygiene & 25 Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom. 26 1 bioRxiv preprint doi: https://doi.org/10.1101/104026; this version posted January 30, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • Receptor for Mouse Hepatitis Virus Is a Member of the Carcinoembryonic Antigen Family of Glycoproteins
    Proc. Natl. Acad. Sci. USA Vol. 88, pp. 5533-5536, July 1991 Medical Sciences Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins (coronavirus/immunoglobulin superfamily/host resistance to virus/virus tissue tropism/virus receptor) RICHARD K. WILLIAMS, GUI-SEN JIANG, AND KATHRYN V. HOLMES* Department of Pathology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814 Communicated by Dorothy M. Horstmann, April 1, 1991 (receivedfor review February 28, 1991) ABSTRACT The receptor for mouse hepatitis virus binds neither MHV-A59 virus nor anti-receptor mAb CC1, (MHV), a murine coronavirus, is a 110- to 120-kDa glycopro- we postulated that it has a mutation affecting the domain of tein on intestinal brush border membranes and hepatocyte the glycoprotein that normally would bind MHV and mAb membranes. The N-terminal 25-amino acid sequence of immu- CC1 (4). In this communication we demonstrate that the noaffinity-purified MHV receptor was identical to the pre- MHV receptor glycoprotein of BALB/c and Swiss Webster dicted mature N termini of two mouse genes related to human mice and its SJL/J homolog are members of the carcinoem- carcinoembryonic antigen (CEA) and was strongly homologous bryonic antigen (CEA) family of glycoproteins in the immu- to the N termini of members of the CEA family in humans and noglobulin superfamily. rats. Polyclonal antibodies to human CEA recognized the immunoaffinity-purified MHV receptor and the MHV receptor in liver membranes and intestinal brush border membranes MATERIALS AND METHODS from MHV-susceptible mouse strains. In membranes from Tissue Preparations and Tissue-Binding Assay.
    [Show full text]
  • Canalicular Immunostaining of Aminopeptidase N (CD13) As a Diagnostic Marker for Hepatocellular Carcinoma Cro¨Cken, J Licht, a Roessner, S Carl-Mcgrath
    1069 J Clin Pathol: first published as 10.1136/jcp.2005.026328 on 27 September 2005. Downloaded from ORIGINAL ARTICLE Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma CRo¨cken, J Licht, A Roessner, S Carl-McGrath ............................................................................................................................... J Clin Pathol 2005;58:1069–1075. doi: 10.1136/jcp.2005.026328 Background: Aminopeptidase N (CD13) is expressed in normal and neoplastic liver tissue, where it exhibits a characteristic canalicular pattern (CD13can), similar to that seen for CD10 and when antibodies crossreact with biliary glycoprotein I (p-CEA). Aim: To compare the putative diagnostic use of CD13can in differentiating between hepatocellular (HCC) See end of article for authors’ affiliations and non-hepatocellular carcinomas metastatic to the liver (non-HCC). ....................... Methods: Aretrospectivestudycomparing53HCCspecimenswith32non-HCCspecimens. Immunostaining was performed with HepPar1 and antibodies directed against CD10, CD13, p-CEA, Correspondence to: Professor C Ro¨cken, and a fetoprotein (AFP). Department of Pathology, Results: In the HCC group, a canalicular staining pattern was found for CD13, p-CEA, and CD10 in 51, Otto-von-Guericke- 43, and 33 specimens, respectively. HepPar1 was positive in 29 and AFP in 17 HCC specimens. In the University, Leipziger Str. non-HCC group, canalicular immunostaining for CD10 and p-CEA was confined to non-neoplastic liver 44, D-39120 Magdeburg, Germany; christoph. tissue. One poorly differentiated cholangiocarcinoma showed apical expression of CD13, resembling to [email protected] some extent CD13can. Sensitivity and specificity were 96.2% and 97.0%, respectively, for CD13can, 81.1% magdeburg.de and 100% for p-CEAcan, 62.3% and 100%, for CD10can, 54.7% and 99.9% for HepPar1, and 32.1% and 100% for AFP.
    [Show full text]
  • A Comparison of CD10 to Pcea, MOC-31, and Hepatocyte for The
    A Comparison of CD10 to pCEA, MOC-31, and Hepatocyte for the Distinction of Malignant Tumors in the Liver Carl Morrison, M.D., D.V.M., William Marsh, Jr, M.D., Wendy L. Frankel, M.D. Department of Pathology, The Ohio State University, College of Medicine, Columbus, Ohio KEY WORDS: CD10, Hepatocellular carcinoma, He- The distinction of hepatocellular carcinoma (HCC) patocyte, MOC31, pCEA. from metastatic adenocarcinoma (MA) and cholan- Mod Pathol 2002;15(12):1279–1287 giocarcinoma (CC) in some cases requires the use of immunohistochemistry. CD10 has recently been The distinction of hepatocellular carcinoma (HCC) suggested as a useful stain for HCC. We directly from metastatic adenocarcinoma (MA) and cholan- compared CD10 with other immunohistochemical giocarcinoma (CC) is often straightforward but can markers, Hepatocyte, pCEA, and MOC31, that have be problematic when either the tumor is poorly previously shown to be useful for the distinction differentiated or a small biopsy is submitted. The between tumors in the liver to help define the cur- antibodies that have been suggested as useful in the rent panel of stains that most readily distinguishes distinction of hepatocellular carcinoma from met- HCC from CC and MA. One hundred previously astatic adenocarcinoma and cholangiocarcinoma well-characterized tumors in the liver were evalu- are numerous and include cytokeratins 7, 8, 18, 19, ated and included 25 HCC, 15 CC, and 60 MAs (15 and 20; alpha-fetoprotein (AFP); Ber-EP4; Factor each from breast, esophageal/gastric, pancreatic, XIIIa; polyclonal carcinoembryonic antigen (pCEA); and colorectal origin). Tumors were immuno- and MOC31, among others (1, 2). Previously, the stained with the commercially available antibodies most commonly used markers in this setting were Hepatocyte, pCEA, MOC31, and CD10.
    [Show full text]
  • CEA-, Her2/Neu-, BCRP- and Hsp27-Positive Microparticles in Breast Cancer Patients*
    ANTICANCER RESEARCH 30: 1707-1712 (2010) CEA-, Her2/neu-, BCRP- and Hsp27-positive Microparticles in Breast Cancer Patients* SUSANNE LIEBHARDT1, NINA DITSCH1, RIENK NIEUWLAND2, ANDREAS RANK3, UDO JESCHKE4, FRANZ VON KOCH5, KLAUS FRIESE1 and BETTINA TOTH6 1Department of Obstetrics and Gynecology - Großhadern, and 3Department of Internal Medicine III – Großhadern, Ludwig Maximilians University, 81377 Munich, Germany; 2Department of Clinical Chemistry, Academic Medical Center 1105 AZ Amsterdam, the Netherlands; 4Department of Obstetrics and Gynecology – Maistrasse, Ludwig Maximilians University, 80337 Munich, Germany; 5Department of Obstetrics and Gynecology, Klinikum Oritter Orden, 80638 Munich, Germany; 6Department of Gynecological Endocrinology and Reproductive Medicine, Ruprecht Karls University, 69115 Heidelberg, Germany Abstract. Background: This is the first prospective case- So far, the only serum tumour markers for breast cancer are control study that evaluates the expression of tumour-specific cancer antigen (CA) 15-3 and carcinoembryonic antigen antigens on circulating microparticles (MP) in breast cancer (CEA). Neither marker is used in diagnosis of primary breast patients and in women with benign breast tumour. Materials cancer but only to diagnose recurrent disease and to evaluate and Methods: MP were determined by flow cytometry in response to chemotherapy (1). Prognostic factors for breast patients with breast cancer (n=34; T1 (n=19) and T2 (n=15)) cancer are the status of axillary lymph nodes, age, tumour and women with benign breast tumour (n=19). Results: load and histological parameters (2), urokinase-type Patients with lymph node metastases (N1, n=9) showed plasminogen activator (uPA) and its inhibitor (PAI-1) (3), significantly higher numbers of annexin V+ MP (p=0.042), and the presence of bone marrow micrometastases (4).
    [Show full text]
  • Evaluation of Serum CEA, CA19-9, CA72-4, CA125 And
    www.nature.com/scientificreports OPEN Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Received: 20 October 2017 Accepted: 26 January 2018 Clinical Parameters for Colorectal Published: xx xx xxxx Cancer Yanfeng Gao1, Jinping Wang2, Yue Zhou3, Sen Sheng4, Steven Y. Qian5 & Xiongwei Huo6 Blood-based protein biomarkers have recently shown as simpler diagnostic modalities for colorectal cancer, while their association with clinical pathological characteristics is largely unknown. In this study, we not only examined the sensitivity and reliability of single/multiple serum markers for diagnosis, but also assessed their connection with pathological parameters from a total of 279 colorectal cancer patients. Our study shown that glycoprotein carcinoembryonic antigen (CEA) owns the highest sensitivity among single marker in the order of CEA > cancer antigen 72-4 (CA72-4) > cancer antigen 19-9 9 (CA19-9) > ferritin > cancer antigen 125 (CA125), while the most sensitive combined-markers for two to fve were: CEA + CA72-4; CEA + CA72-4 + CA125; CEA + CA19-9 + CA72-4 + CA125; and CEA + CA19-9 + CA72-4 + CA125 + ferritin, respectively. We also demonstrated that patients who had positive preoperative serum CEA, CA19-9, or CA72-4 were more likely with lymph node invasion, positive CA125 were prone to have vascular invasion, and positive CEA or CA125 were correlated with perineural invasion. In addition, positive CA19-9, CA72-4, or CA125 was associated with poorly diferentiated tumor, while CEA, CA19-9, CA72-4, CA125 levels were positively correlated with pathological tumor-node-metastasis stages. We here conclude that combined serum markers can be used to not only diagnose colorectal cancer, but also appraise the tumor status for guiding treatment, evaluation of curative efect, and prognosis of patients.
    [Show full text]